Anja Poulsen

Dr. Anja Poulsen

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Vaccine
Verified
Journal Article
Closed access
LSLone Graff Stensballe
Lone Graff Stensballe
ENErnesto Nante
Ernesto Nante
IJInge Panum Jensen
Inge Panum Jensen
PKPoul-Erik Kofoed
Poul-Erik Kofoed
APAnja Poulsen
Anja Poulsen
PAPeter Aaby
Peter Aaby

1 December 2001 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
BCB V Cam
B V Cam
LFL Fonsmark
L Fonsmark
NHN B Hue
N B Hue
NPN T Phuong
N T Phuong
APAnja Poulsen
Anja Poulsen
EHE D Heegaard
E D Heegaard
We present a prospective case-control study of 27 serologically confirmed dengue hemorrhagic fever (DHF) patients with severe central nervous system symptoms. Dengue associated encephalopathy accounted for 0.5% of 5,400 patients admitted with DHF. The mortality rate among children with encephalopathy was 22%, with the survivors experiencing a complete recovery. Liver enzymes and bilirubin were significantly elevated in the study group. In analysis of the cerebrospinal fluid (CSF), reverse transcriptase-polymerase chain reaction revealed dengue-3-specific RNA in one evaluated case. Dengue-specific immunoglobulin M was detected in CSF in 14 of 22 assessable patients, indicating a localized infection. Magnetic resonance imaging scans showed cerebral edema in the majority of patients, although encephalitis-like changes were less common. There was an equal distribution of primary and secondary infections. On the basis of previous reports and of the findings of our study, DHF probably encompasses an expanding clinical spectrum that infrequently involves encephalitis due to a direct neurotropic effect of dengue virus.

19 January 2005 in International Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
ARAdam Roth
Adam Roth
PGPer Gustafson
Per Gustafson
ANAlexandro Nhaga
Alexandro Nhaga
QDQueba Djana
Queba Djana
APAnja Poulsen
Anja Poulsen
PAPeter Aaby
Peter Aaby
Background Recent studies have suggested that Bacille Calmette–Guerin (BCG) vaccination may have a non-specific beneficial effect on infant survival and that a BCG scar may be associated with lower child mortality. No study has previously examined the influence of BCG vaccination on cause of death. Methods Two cohorts (A and B) were used to describe the mortality pattern for children with and without BCG scar and to determine specific causes of death. In cohort A (n = 1813), BCG scar was assessed at 6 months of age and as previously described children with a BCG scar had lower mortality over the next 12 months than children with no BCG scar. In cohort B, 1617 children aged 3 months to 5 years of age had their BCG scar status assessed in a household-based survey and mortality was assessed during a 12-month period. Causes of death were determined by verbal autopsy (VA) and related to BCG scar status in a cause-specific hazard function. Results Controlling for background factors associated with mortality, there was lower mortality for children with a BCG scar than without in cohort B, the mortality ratio (MR) being 0.45 (95% CI 0.21–0.96). Exclusion of children exposed to TB did not have any impact on the result. In a combined analysis of cohorts A and B, the MR was 0.43 (95% CI 0.28–0.65) controlling for background factors. There were no large differences in distribution of the five major causes of death (malaria, pneumonia, acute diarrhoea, chronic diarrhoea, and meningitis/encephalitis) according to BCG scar status in the two cohorts. Having a BCG scar significantly reduced the risk of death from malaria [MR 0.32 (95% CI 0.13–0.76)]. Conclusions A BCG scar is a marker of better survival among children in countries with high child mortality. BCG vaccination may affect the response to several major infections including malaria.

1 June 2003 in The Lancet
Verified
Journal Article
Closed access
PAPeter Aaby
Peter Aaby
HJHenrik Jensen
Henrik Jensen
BSBadara Samb
Badara Samb
BCBadara Cisse
Badara Cisse
MSMorten Sodemann
Morten Sodemann
HWHilton Whittle
Hilton Whittle

26 February 2014 in JAMA
Verified
Journal Article
Closed access
PDF file
SSSigne Sørup
Signe Sørup
CBChristine S. Benn
Christine S. Benn
APAnja Poulsen
Anja Poulsen
TKTyra G. Krause
Tyra G. Krause
PAPeter Aaby
Peter Aaby
HRHenrik Ravn
Henrik Ravn
Research from JAMA — Live Vaccine Against Measles, Mumps, and Rubella and the Risk of Hospital Admissions for Nontargeted Infections

1 March 1997 in The Lancet
Verified
Journal Article
Closed access
APAnja Poulsen
Anja Poulsen
PAPeter Aaby
Peter Aaby
OLOlav Larsen
Olav Larsen
HJHenrik Jensen
Henrik Jensen
ANAnders Nauclér
Anders Nauclér
MMMads Melbye
Mads Melbye